HDAC inhibitors enhance the immunotherapy response of melanoma cells

We focused on the ability of the pan-histone deacetylase (HDAC) inhibitors AR42 and sodium valproate to alter the immunogenicity of melanoma cells. Treatment of melanoma cells with HDAC inhibitors rapidly reduced the expression of multiple HDAC proteins as well as the levels of PD-L1, PD-L2 and ODC,...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669957/
https://www.ncbi.nlm.nih.gov/pubmed/29137331
http://dx.doi.org/10.18632/oncotarget.17950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669957/
https://www.ncbi.nlm.nih.gov/pubmed/29137331
http://dx.doi.org/10.18632/oncotarget.17950

Ejemplares similares